Plain-English translation of NCT07414940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called Actinium-225 rhPSMA-10.1, which uses radioactive energy to target and destroy prostate cancer cells. The medication works similarly to a treatment you may have already received (Lutetium-PSMA), but delivers stronger, more focused energy over a shorter distance. Researchers hope this approach can help men whose cancer has stopped responding to previous treatments.
Some men with advanced prostate cancer eventually stop responding to standard treatments, including a radioactive therapy called Lutetium-PSMA. This trial exists to see whether the new medication — which uses a different type of radioactive energy — can work better for these patients and potentially overcome prior treatment resistance.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication every six weeks, for a maximum of six doses. Before treatment begins, you'll undergo screening tests including blood work and imaging scans to confirm you qualify. During treatment, you'll have weekly check-ins with the trial doctor (sometimes by phone) to monitor how you're tolerating the medication and watch for side effects. Every 12 weeks, you'll have CT and bone scans to see how your cancer is responding. The trial lasts several months, depending on how many doses you receive and how well you tolerate the treatment.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United Kingdom